Daily Stock Analysis, AGRX, Agile Therapeutics Inc, priceseries

Agile Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.39
Close
1.46
High
1.59
Low
1.38
Previous Close
1.36
Daily Price Gain
0.10
YTD High
1.70
YTD High Date
Mar 15, 2019
YTD Low
0.58
YTD Low Date
Jan 2, 2019
YTD Price Change
0.74
YTD Gain
104.20%
52 Week High
1.70
52 Week High Date
Mar 15, 2019
52 Week Low
0.32
52 Week Low Date
Sep 25, 2018
52 Week Price Change
0.91
52 Week Gain
165.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 15. 2017
2.36
Apr 5. 2017
2.96
15 Trading Days
25.24%
Link
LONG
Apr 24. 2017
3.08
May 5. 2017
3.40
9 Trading Days
10.34%
Link
LONG
Jul 12. 2017
3.87
Jul 26. 2017
4.60
10 Trading Days
18.77%
Link
LONG
Sep 20. 2017
3.73
Oct 16. 2017
4.95
18 Trading Days
32.84%
Link
LONG
Nov 17. 2017
4.57
Dec 5. 2017
4.85
11 Trading Days
6.21%
Link
LONG
Mar 8. 2019
1.14
Mar 22. 2019
1.46
10 Trading Days
28.12%
Link
LONG
Jun 10. 2019
1.27
Jul 5. 2019
1.41
18 Trading Days
10.86%
Link
Company Information
Stock Symbol
AGRX
Exchange
NasdaqGM
Company URL
http://www.agiletherapeutics.com
Company Phone
609-683-1880
CEO
Al Altomari
Headquarters
New Jersey
Business Address
101 POOR FARM ROAD, PRINCETON, NJ 08540-1715
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001261249
About

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.

Description

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.